Vutrisiran Wins Fast Track Designation for Polyneuropathy in hATTR Amyloidosis

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.

Source link

Related posts

Editors' note: Insular and anterior cingulate cortex deep stimulation for central neuropathic pain: Disassembling the percept of pain


Spectrum: Stabilizing head mold leads to sharper brain images


Three novel recessive DYSF mutations identified in three patients with muscular dystrophy, limb-girdle, type 2B.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World